Abstract
GABA is the major inhibitory neurotransmitter in the brain and GABA re- uptake from the synaptic cleft is one important mechanism in the regulation of GABA activity. Inhibition of the re-uptake of GABA by potent and selective inhibitors of the GABA transporter enhances GABA activity. This property can be used therapeutically in for instance epilepsy or psychiatric disorders. In this paper putative structures of the GABA transporter, its mechanism of action, the progress made in the search for its amino acids involved in the binding of substrates and the SAR of inhibitors acting at the transporter will be discussed. To date only highly selective GAT-1 inhibitors are available. These compounds are lipophilic derivatives of (R)-nipecotic acid and guvacine. The most potent inhibitors of the cloned human GAT-1 are NNC-711 (IC50 = 0.04 μM) and tiagabine (IC50 = 0.07 μM). A diheteroarylvinyloxy analogue of tiagabine, 5 times more potent than tiagabine, has been reported recently. For the GAT-2, GAT-3 and BGT-1 subtypes only compounds with a small preference for one of the subtypes have been published.
Current Medicinal Chemistry
Title: The GABA Transporter and its Inhibitors
Volume: 7 Issue: 10
Author(s): W. Soudijn and I. van Wijngaarden
Affiliation:
Abstract: GABA is the major inhibitory neurotransmitter in the brain and GABA re- uptake from the synaptic cleft is one important mechanism in the regulation of GABA activity. Inhibition of the re-uptake of GABA by potent and selective inhibitors of the GABA transporter enhances GABA activity. This property can be used therapeutically in for instance epilepsy or psychiatric disorders. In this paper putative structures of the GABA transporter, its mechanism of action, the progress made in the search for its amino acids involved in the binding of substrates and the SAR of inhibitors acting at the transporter will be discussed. To date only highly selective GAT-1 inhibitors are available. These compounds are lipophilic derivatives of (R)-nipecotic acid and guvacine. The most potent inhibitors of the cloned human GAT-1 are NNC-711 (IC50 = 0.04 μM) and tiagabine (IC50 = 0.07 μM). A diheteroarylvinyloxy analogue of tiagabine, 5 times more potent than tiagabine, has been reported recently. For the GAT-2, GAT-3 and BGT-1 subtypes only compounds with a small preference for one of the subtypes have been published.
Export Options
About this article
Cite this article as:
Soudijn W. and van Wijngaarden I., The GABA Transporter and its Inhibitors, Current Medicinal Chemistry 2000; 7 (10) . https://dx.doi.org/10.2174/0929867003374363
DOI https://dx.doi.org/10.2174/0929867003374363 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Voltage-Gated Sodium Channel Blockers; Target Validation and Therapeutic Potential
Current Topics in Medicinal Chemistry Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology Radiofluorinated Carbohydrates for Positron Emission Tomography
Current Topics in Medicinal Chemistry Concurrent Estimation of Gabapentin and Nortriptyline Hydrochloride in their Combined Dosage Form Using OPA-β-Mercaptoethanol Derivatization by Spectrophotometric and Spectrofluorimetric Methods
Current Pharmaceutical Analysis Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Molecular Biotheranostic Approaches of Cancers Using LAT Kit Probes
Current Medical Imaging Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Novel Pharmacological Targets From Indian Cone Snails
Mini-Reviews in Medicinal Chemistry Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Preface
Current Medical Imaging RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design